argenx

ISIN US04016X1019

 | 

Code du titre A2H9WD

Cap. boursière (en EUR)
40,596 m
Country
Netherlands
Secteur
Healthcare
Rendement en dividendes
0.00%
 

Aperçu

Description

argenx SE is a global immunology company, which engages in improving the lives of people suffering from severe autoimmune diseases. It operates through the following geographical segments: United States, Japan, EMEA, and China. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren in 2008 and is headquartered in Amsterdam, the Netherlands.
Afficher plus Afficher moins
Healthcare Biopharmaceuticals System-Specific Biopharmaceuticals Netherlands

Données financières

Indicateurs clés

Capitalisation boursière, EUR 40,596 m
BPA, EUR -
Ratio cours/valeur comptable 6.6
PER 36.7
Rendement en dividendes 0.00%

Income statement (2025)

Chiffre d'affaires, EUR 3,693 m
Résultat net, EUR 1,149 m
Marge bénéficiaire 31.11%

What ETF is argenx in?

There are 4 ETFs which contain argenx. All of these ETFs are listed in the table below. The ETF with the largest weighting of argenx is the iShares Nasdaq US Biotechnology UCITS ETF USD (Dist).
ETF Poids Objectif d'investissement Taille fonds en M €
Goldman Sachs Paris-Aligned Climate World Equity UCITS ETF USD (Acc) 0.10%
Equity
World
Social/Environmental
Climate Change
7
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) 1.66%
Equity
United States
Health Care
Biotech
46
Amundi Prime Eurozone UCITS ETF DR (D) 0.64%
Equity
Europe
73
Amundi Prime Europe UCITS ETF DR (D) 0.33%
Equity
Europe
226
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH.

Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.